Sacituzumab Earns Regular FDA Approval for TNBC - NCI
Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic
Therapeutic efficacy of IMMU-132 with different DARs. NCI-N87
PDF) Metastatic Triple-Negative Breast Cancer
Mission Mountain Wilderness
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic
Targeted therapy for breast cancer: An overview of drug classes
Triple negative breast cancer and non-small cell lung cancer
Mission Mountain Wilderness
Pharmaceutics, Free Full-Text
Triple Negative Breast Cancer Archives - Tigerlily Foundation
Biomolecules, Free Full-Text
Sacituzumab govitecan in metastatic triple negative breast cancer
Triple negative breast cancer: Pitfalls and progress